References
1. Pandit S., Boktor M., Alexander J.S. et al. (2018) Gastroesophageal Reflux Disease: A Clinical Overview for Primary Care Physicians. Pathophysiology, 25(1): 1–11. doi: 10.1016/j.pathophys.2017.09.001.
2. El-Serag H.B., Sweet S., Winchester C.C., Dent J. (2014) Update on the epidemiology of gastro-oesophageal reflux disease: a systematic review. Gut, 63: 871–80. doi: 10.1136/gutjnl-2012-304269.
3. GBD 2017 Gastro-oesophageal Reflux Disease Collaborators (2020) The global, regional, and national burden of gastro-oesophageal reflux disease in 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet Gastroenterol Hepatol., 5(6): 561–581. doi: 10.1016/S2468-1253(19)30408-X.
4. Ofman J.J. (2003) The Economic and Quality-of- Life Impact of Symptomatic Gastroesophageal Reflux Disease. Am. J. Gastroenterol., 98(3 Suppl.): S8–S14. doi: 10.1016/s0002-9270(03)00010-8.
5. Eslick G.D., Talley N.J. (2009) Gastroesophageal reflux disease (GERD): risk factors, and impact on quality of life-a population-based study. J. Clin. Gastroenterol., 43(2): 111–117. doi: 10.1097/MCG.0b013e31815ea27b.
6. Fashner J. (2020) Gastroesophageal Reflux Disease: A General Overview. HCA Healthc J. Med., 1(4): 191–199. doi: 10.36518/2689-0216.1042.
7. Rochoy M., Dubois S., Glantenet R. et al. (2018) Le rebond d’acidité gastrique après arrêt d’un inhibiteur de la pompe à protons : revue narrative de littérature [Gastric acid rebound after a proton pump inhibitor: Narrative review of literature]. Therapie, 73(3): 237–246. doi: 10.1016/j.therap.2017.08.005.
8. Agwaonye S., Vasant D.H. (2023) Optimising reflux symptom burden and patient compliance during PPI washout periods for oesophageal pH monitoring studies: should we be more proactive with alginate use? BMJ Open Gastroenterol., 10(1): e001078. doi: 10.1136/bmjgast-2022-001078.
9. Dunbar K., Yadlapati R., Konda V. (2022) Heartburn, Nausea, and Vomiting During Pregnancy. Am. J. Gastroenterol., 117(10S): 10–15. doi: 10.14309/ajg.0000000000001958.
10. Dekkers G.W.F., Broeren M.A.C., Truijens S.E.M. et al. (2020) Hormonal and psychological factors in nausea and vomiting during pregnancy. Psychol. Med., 50(2): 229–236. doi: 10.1017/S0033291718004105.
11. Strugala V., Bassin J., Swales V.S. et al. (2012) Assessment of the Safety and Efficacy of a Raft Forming Alginate Reflux Suppressant (Liquid Gaviscon) for the Treatment of Heartburn during Pregnancy. ISRN Obstet. Gynecol., 2012: 481870. doi: 10.5402/2012/481870.
12. Щербинина М.Б., Луговская Т.В., Иванченко Н.А., Коваленко Г.А. (2016) Оценка эффективности препарата Гавискон Форте в терапии изжоги беременных. Здоровье женщины, 7: 84–90.
13. Katz P.O., Dunbar K.B., Schnoll-Sussman F.H. et al. (2022) ACG Clinical Guideline for the Diagnosis and Management of Gastroesophageal Reflux Disease. Am. J. Gastroenterol., 117(1): 27–56. doi: 10.14309/ajg.0000000000001538.
14. Razgallah N., Galasso D., Le Bloc’h F., Firmann M. (2023) Utilisation des inhibiteurs de la pompe à protons en pratique [Practice review on the use of proton pump inhibitors]. Rev. Med. Suisse, 19(814): 340–345. doi: 10.53738/REVMED.2023.19.814.340.
15. Poddar U. (2019) Gastroesophageal reflux disease (GERD) in children. Paediatr. Int. Child Health, 39(1): 7–12. doi: 10.1080/20469047.2018.1489649.
16. Choi Y.J., Ha E.K., Jeong S.J. (2016) Dietary habits and gastroesophageal reflux disease in preschool children. Korean J. Pediatr., 59(7): 303–307. doi: 10.3345/kjp.2016.59.7.303.
17. Winter H.S., Illueca M., Henderson C., Vaezi M. (2011) Review of the persistence of gastroesophageal reflux disease in children, adolescents and adults: does gastroesophageal reflux disease in adults sometimes begin in childhood? Scand J. Gastroenterol., 46(10): 1157–1168. doi: 10.3109/00365521.2011.591425.
18. Krause A.J., Walsh E.H., Weissbrod P.A. et al. (2022) An update on current treatment strategies for laryngopharyngeal reflux symptoms. Ann. N.Y. Acad. Sci., 1510(1): 5–17. doi: 10.1111/nyas.14728.
19. Koufman J.A. (1991) The otolaryngologic manifestations of gastroesophageal reflux disease (GERD): a clinical investigation of 225 patients using ambulatory 24-hour pH monitoring and an experimental investigation of the role of acid and pepsin in the development of laryngeal injury. Laryngoscope, 101(4 Pt. 2 Suppl. 53): 1–78. doi: 10.1002/lary.1991.101.s53.1.
20. Wright R.A., Miller S.A., Corsello B.F. (1990) Acid-induced esophagobronchial-cardiac reflexes in humans. Gastroenterology, 99(1): 71–73. doi: 10.1016/0016-5085(90)91231-t.
21. McGlashan J.A., Johnstone L.M., Sykes J. et al. (2009) The value of a liquid alginate suspension (Gaviscon Advance) in the management of laryngopharyngeal reflux. Eur. Arch. Otorhinolaryngol., 266(2): 243–251. doi: 10.1007/s00405-008-0708-7.
22. Lechien J.R., Bock J.M., Carroll T.L., Akst L.M. (2020) Is empirical treatment a reasonable strategy for laryngopharyngeal reflux? A contemporary review. Clin. Otolaryngol., 45(4): 450–458. doi.org/10.1111/coa.13518.
23. Reimer C., Lødrup A.B., Smith G. et al. (2016) Randomised clinical trial: alginate (Gaviscon Advance) vs. placebo as add-on therapy in reflux patients with inadequate response to a once daily proton pump inhibitor. Aliment. Pharmacol. Ther., 43(8): 899–909. doi: 10.1111/apt.13567.
24. Wilkinson J., Wade A., Thomas S.J. et al. (2019) Randomized clinical trial: a double-blind, placebo-controlled study to assess the clinical efficacy and safety of alginate-antacid (Gaviscon Double Action) chewable tablets in patients with gastro-oesophageal reflux disease. Eur. J. Gastroenterol. Hepatol., 31(1): 86–93. doi: 10.1097/MEG.0000000000001258.
25. Chen J.W., Vela M.F., Peterson K.A., Carlson D.A. (2023) AGA Clinical Practice Update on the Diagnosis and Management of Extraesophageal Gastroesophageal Reflux Disease: Expert Review. Clin. Gastroenterol. Hepatol., 21(6): 1414–1421.e3. doi: 10.1016/j.cgh.2023.01.040.
26. Vales A., Coyle C., Plehhova K. et al. (2023) Randomised clinical trial: the use of alginates during preinvestigation proton pump inhibitor wash-out and their impact on compliance and symptom burden. BMJ Open Gastroenterol., 10(1): e001026. doi: 10.1136/bmjgast-2022-001026.
27. Hungin A.P.S., Molloy-Bland M., Scarpignato C. (2019) Revisiting Montreal: New Insights into Symptoms and Their Causes, and Implications for the Future of GERD. Am. J. Gastroenterol., 114(3): 414–421. doi: 10.1038/s41395-018-0287-1.